Detalhe da pesquisa
1.
Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma.
Ann Oncol
; 28(5): 1057-1063, 2017 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28327905
2.
Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.
Ann Oncol
; 27(5): 895-901, 2016 05.
Artigo
Inglês
| MEDLINE | ID: mdl-26802151
3.
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.
Ann Oncol
; 27(7): 1317-23, 2016 07.
Artigo
Inglês
| MEDLINE | ID: mdl-27091808
4.
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Ann Oncol
; 23(6): 1640-5, 2012 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-22015451
5.
Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53.
Cancer Gene Ther
; 13(8): 806-14, 2006 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-16628227
6.
Efficacy and safety of antiretrovirals in HIV-infected patients with cancer.
Clin Microbiol Infect
; 20(10): O672-9, 2014 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-24529214